![Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs](https://www.frontiersin.org/files/Articles/1010808/fimmu-13-1010808-HTML/image_m/fimmu-13-1010808-g001.jpg)
Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs
![Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes](https://www.frontiersin.org/files/Articles/1093385/fimmu-14-1093385-HTML/image_m/fimmu-14-1093385-t001.jpg)
Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes
![Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs](https://www.frontiersin.org/files/MyHome%20Article%20Library/1010808/1010808_Thumb_400.jpg)
Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs
localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles
![Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes](https://www.frontiersin.org/files/Articles/1093385/fimmu-14-1093385-HTML/image_m/fimmu-14-1093385-t004.jpg)
Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes
![Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes](https://www.frontiersin.org/files/Articles/1093385/fimmu-14-1093385-HTML/image_m/fimmu-14-1093385-g002.jpg)
Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes
localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles
![Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs](https://www.frontiersin.org/files/Articles/1010808/fimmu-13-1010808-HTML/image_m/fimmu-13-1010808-g005.jpg)
Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs
localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles
![Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs](https://www.frontiersin.org/files/Articles/1010808/fimmu-13-1010808-HTML/image_m/fimmu-13-1010808-g002.jpg)
Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs
localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles
localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles
![Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes](https://www.frontiersin.org/files/Articles/1093385/fimmu-14-1093385-HTML/image_m/fimmu-14-1093385-g001.jpg)
Frontiers | A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes
![Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs Frontiers | Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs](https://www.frontiersin.org/files/Articles/1010808/fimmu-13-1010808-HTML/image_m/fimmu-13-1010808-g003.jpg)